gp91ds-tat

gp91ds-tat is a synthetic peptide and a selective inhibitor of NADPH oxidase 2 (NOX2), also referred to as gp91phox. The compound functions by mimicking the region of gp91phox that interacts with p47phox, thereby competitively inhibiting the assembly and activation of the NADPH oxidase complex. By blocking NOX2 activity, it reduces the production of reactive oxygen species (ROS). NOX2 is implicated in the pathology of diseases involving oxidative stress, such as epilepsy, neurodegenerative disorders (including Alzheimer's disease), and inflammatory kidney or muscle disease. gp91ds-tat is typically administered via intravenous or intranasal routes in preclinical settings due to its peptide nature and poor oral bioavailability. Originally developed at Yissum Research Development Co., gp91ds-tat has shown efficacy in various animal models and is a tool compound for research and early-stage preclinical development[3][5][6][4][7][1].

Other names

gp91-dstatgp-91-dstatgp 91-dstatgp91 ds-tatgp-91 ds-tatgp 91 ds-tatGP91DS-TATGP-91DS-TATGP 91DS-TATGP91DSTATGP-91DSTATGP 91DSTAT